What does Dr. Vandeputte-Dr. Verleure do?

Dr. Vandeputte-Dr. Verleure is a general practice in Deerlijk. Private Limited, started on 27 November 2018, 1 establishment.

What is the address of Dr. Vandeputte-Dr. Verleure?

The registered office of Dr. Vandeputte-Dr. Verleure is located at Pontstraat 45, 8540 Deerlijk.

Is Dr. Vandeputte-Dr. Verleure still active?

Yes. According to the CBE (29 September 2026) Dr. Vandeputte-Dr. Verleure is active, legal situation “Normale toestand”, started on 27 November 2018.

Is Dr. Vandeputte-Dr. Verleure registered on Peppol?

Yes, Dr. Vandeputte-Dr. Verleure is registered on the Peppol network with ID 0208:0713962164.

What is the enterprise number of Dr. Vandeputte-Dr. Verleure?

The enterprise number of Dr. Vandeputte-Dr. Verleure is BE0713962164.

When was Dr. Vandeputte-Dr. Verleure founded?

Dr. Vandeputte-Dr. Verleure was founded on 27 November 2018.

Who are the directors of Dr. Vandeputte-Dr. Verleure?

According to the 2025 annual accounts, the directors of Dr. Vandeputte-Dr. Verleure are: NICOLAS VANDEPUTTE, LEEN VERLEURE.

Is Dr. Vandeputte-Dr. Verleure a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 November 2018; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Dr. Vandeputte-Dr. Verleure make in 2025?

Dr. Vandeputte-Dr. Verleure posted a profit after taxes of € 94,832 in financial year 2025.

What is the revenue of Dr. Vandeputte-Dr. Verleure?

As a small company, Dr. Vandeputte-Dr. Verleure is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 222,726.

Dr. Vandeputte-Dr. Verleure (Private Limited) - Deerlijk

Dossier Dr. Vandeputte-Dr. Verleure, printed on 29 September 2026 from databakkes.be/en/0713962164/dr-vandeputte-dr-verleure. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Vandeputte-Dr. Verleure from Deerlijk, company number BE0713962164, closed financial year 2025 with a result of € 94,832 after tax. For that financial year Dr. Vandeputte-Dr. Verleure recorded a gross margin of € 222,726 and equity of € 68,600. Compared with financial year 2024, the result moved from € 26,396 to € 94,832. Profitable, and profit is growing. The buffer shrank hard: equity is 59 % below last year. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.

What it is worth Shrank hard

€ 68,600

▼ 59% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 94,832

▲ 259% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 216,575

▲ 37% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 194,388 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Wage cost

€ 40,986

▲ 38% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 10,393

▼ 60% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3,086

▲ 195% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 13,328

▼ 14% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 229,987 Gross margin 2022: € 229,987 First fiscal year in the series	€ 114,731 Gross margin 2023: € 114,731 ▼ 50% vs 2022 (€ 229,987) Unfavourable step	€ 121,300 Gross margin 2024: € 121,300 ▲ 6% vs 2023 (€ 114,731) Favourable step	€ 222,726 Gross margin 2025: € 222,726 ▲ 84% vs 2024 (€ 121,300) Favourable step	▲ 84%
Profit after taxes	€ 118,350 Profit after taxes 2022: € 118,350 First fiscal year in the series	€ 14,385 Profit after taxes 2023: € 14,385 ▼ 88% vs 2022 (€ 118,350) Unfavourable step	€ 26,396 Profit after taxes 2024: € 26,396 ▲ 83% vs 2023 (€ 14,385) Favourable step	€ 94,832 Profit after taxes 2025: € 94,832 ▲ 259% vs 2024 (€ 26,396) Favourable step	▲ 259%
Equity	€ 259,172 Equity 2022: € 259,172 First fiscal year in the series	€ 190,096 Equity 2023: € 190,096 ▼ 27% vs 2022 (€ 259,172) Unfavourable step	€ 168,157 Equity 2024: € 168,157 ▼ 12% vs 2023 (€ 190,096) Unfavourable step	€ 68,600 Equity 2025: € 68,600 ▼ 59% vs 2024 (€ 168,157) Unfavourable step	▼ 59%
Total debts	€ 398,939 Total debts 2022: € 398,939 First fiscal year in the series	€ 317,760 Total debts 2023: € 317,760 ▼ 20% vs 2022 (€ 398,939) Favourable step	€ 152,756 Total debts 2024: € 152,756 ▼ 52% vs 2023 (€ 317,760) Favourable step	€ 279,970 Total debts 2025: € 279,970 ▲ 83% vs 2024 (€ 152,756) Unfavourable step	▲ 83%
Cash	€ 402,913 Cash 2022: € 402,913 First fiscal year in the series	€ 136,764 Cash 2023: € 136,764 ▼ 66% vs 2022 (€ 402,913) Unfavourable step	€ 157,988 Cash 2024: € 157,988 ▲ 16% vs 2023 (€ 136,764) Favourable step	€ 216,575 Cash 2025: € 216,575 ▲ 37% vs 2024 (€ 157,988) Favourable step	▲ 37%
Retained profit	€ 240,572 Retained profit 2022: € 240,572 First fiscal year in the series	€ 171,496 Retained profit 2023: € 171,496 ▼ 29% vs 2022 (€ 240,572) Unfavourable step	€ 149,557 Retained profit 2024: € 149,557 ▼ 13% vs 2023 (€ 171,496) Unfavourable step	€ 50,000 Retained profit 2025: € 50,000 ▼ 67% vs 2024 (€ 149,557) Unfavourable step	▼ 67%
Dividend	€ 120,000 Dividend 2022: € 120,000 First fiscal year in the series	€ 83,461 Dividend 2023: € 83,461 ▼ 30% vs 2022 (€ 120,000) Unchanged	€ 48,336 Dividend 2024: € 48,336 ▼ 42% vs 2023 (€ 83,461) Unchanged	€ 194,388 Dividend 2025: € 194,388 ▲ € 146,053 vs 2024 (€ 48,336) Unchanged	▲ € 146,053
Bank debt	€ 70,824 Bank debt 2022: € 70,824 First fiscal year in the series	€ 40,649 Bank debt 2023: € 40,649 ▼ 43% vs 2022 (€ 70,824) Favourable step	€ 10,207 Bank debt 2024: € 10,207 ▼ 75% vs 2023 (€ 40,649) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 10,207) Favourable step	▼ 100%
Balance sheet total	€ 658,111 Balance sheet total 2022: € 658,111 First fiscal year in the series	€ 507,855 Balance sheet total 2023: € 507,855 ▼ 23% vs 2022 (€ 658,111) Unchanged	€ 320,913 Balance sheet total 2024: € 320,913 ▼ 37% vs 2023 (€ 507,855) Unchanged	€ 348,570 Balance sheet total 2025: € 348,570 ▲ 9% vs 2024 (€ 320,913) Unchanged	▲ 9%

Key figures of Dr. Vandeputte-Dr. Verleure, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Vandeputte-Dr. Verleure?

What happened at Dr. Vandeputte-Dr. Verleure in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 14, 2026 New annual accounts for financial year 2025: profit of € 94,832 (▲ 259% vs 2024). Source: NBB ↗
Jan 1, 2019 New establishment in Deerlijk. KBO
2018 NICOLAS VANDEPUTTE became a director. NBB
2018 LEEN VERLEURE became a director. NBB
Nov 27, 2018 Start of the company according to the CBE. KBO

In short

From € 118,350 profit in 2022 to € 94,832 profit in 2025.

Paid € 77,682 in corporate taxes since 2022.

Best year ever: 2022, with € 118,350 profit.

Paid out € 446,185 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Vandeputte-Dr. Verleure? We notify you, reason included.

Follow Dr. Vandeputte-Dr. Verleure

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

NICOLAS VANDEPUTTE LEEN VERLEURE

Dr. Vandeputte-Dr. Verleure

Behind Dr. Vandeputte-Dr. Verleure are NICOLAS VANDEPUTTE and LEEN VERLEURE.

See the full network in the app

Directors

According to the 2025 annual accounts

NICOLAS VANDEPUTTE

Director

since 2018

LEEN VERLEURE

Director

since 2018

Establishments

Establishment units

Physical locations of this company

Registered office

Pontstraat 45

8540 Deerlijk

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0713.962.164
VAT number: BE 0713.962.164
Registered office: Pontstraat 45, 8540 Deerlijk
Names & denominations: Dr. Vandeputte-Dr. Verleure
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 27 November 2018
Peppol: Active · Active since 20 Oct 2025
Activities · NACE: Activiteiten van huisartspraktijken

View on CBE Public ↗ Annual accounts (NBB) ↗